A study to verify the acute therapeutic effect of mepolizumab for eosinophilicpolyangiitis granulomatosis (EGPA) neuropathy(A Prospective Observational Study)

Not Applicable

Recruiting

Conditions: Eosinophilic granulomatosis with polyangiitis
D015267

Registration Number: JPRN-jRCT1061230097

Lead Sponsor: Takeshita Yukio

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 20

Inclusion Criteria

1) Patients =<30 day after onset of EGPA neuropathy.
2) Patients who treated with steroid-pulse therapy (3 days) during the acute phase of EGPA neuropathy and shown no complete remission in EGPA neuropathy.
3) Patients who meet the American Society of Rheumatology EGPA classification criteria or American College of Rheumatology/European League Against Rheumatism EGPA classification criteria.
4) Patients aged 20 years or older at the time of onset of EGPA neuropathy.
5) Regardless of gender.
6) Patients who gave informed consent to participate in the study by the patient or the legally acceptable
representative after receiving adequate explanation for their participation in the study.

Exclusion Criteria

1) Patients being treated with mepolizumab
2) Patients who received steroid-pulse therapy (3 days) in the acute phase of EGPA neuropathy and had complete EGPA neuropaty resolution.
3) Life-threatening patients
4) Patients who were judged inappropriate by principal investigator

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of peripheral nerve recovery rate, electrical diagnosis rate of peripheral nerve recovery, peripheral blood eosinophil count, and relapse rate with previous results.

Secondary Outcome Measures